New Finance Manager assumes office at Scandinavian ChemoTech
ChemoTechs deputy CFO, Annette Colin, leaves her assignment after expired contract as agreed.
Ann Ohlsson will take up the position as Finance Manager at ChemoTech.
We thank Annette for her efforts and welcomes Ann to the company.
For more information, please contact:
Mohan Frick, Co-Founder and CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: firstname.lastname@example.org
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Wednesday March 18th 2020 at 10.45 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.